Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Você está prestes a deixar o site local do Brasil e será direcionado ao site global. Deseja continuar?
Não exibir esta mensagem novamente
Sim
Não

Voce Buscou por:

You Searched For:

INFORMAÇÕES RELACIONADAS

CONTATOS PRINCIPAIS

PRÓXIMOS EVENTOS

PRODUTOS RELACIONADOS

Produtos Farmacêuticos - Bermuda

Destaques

Relatórios
Empresas
Refine sua pesquisa por Segmento de Mercado para obter a Atividade de Rating e Watchlist correspondentes
  DataTipo de Documento Título Emissor/Entidade
16 Feb 2024 Rating Action Moody's upgrades Novartis' rating to Aa3 and changes its outlook to stable Novartis AG
Novartis Capita...
Novartis Financ...
Novartis Financ...
Novartis Securi...
14 Dec 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Pharmaceutical issuers ADVANZ PHARMA H...
AI Sirona (Luxe...
Almirall, S.A.
AstraZeneca Fin...
AstraZeneca PLC
Cerebro HoldCo ...
Cheplapharm Arz...
Cidron Aida Fin...
Covis Finco S.a...
Covis Parent SC...
...
11 Dec 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Conglomerates, Investment Holding, Pharmaceuticals and Other issuers in Asia Pacific Astellas Pharma...
Baxalta Incorpo...
Beijing Capital...
Beijing Capital...
China Jianyin I...
CK Hutchison Ca...
CK Hutchison Eu...
CK Hutchison Eu...
CK Hutchison Fi...
CK Hutchison Fi...
...
27 Mar 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Pharmaceutical issuers ADVANZ PHARMA H...
AI Sirona (Luxe...
Almirall, S.A.
AstraZeneca Fin...
AstraZeneca PLC
Cerebro HoldCo ...
Cheplapharm Arz...
Cidron Aida Fin...
Covis Finco S.a...
Covis Parent SC...
...
10 Feb 2023 Rating Action Moody's affirms Novartis' A1 rating; changes outlook to positive Novartis AG
Novartis Capita...
Novartis Financ...
Novartis Financ...
Novartis Securi...
23 Jan 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Conglomerates, Investment Holding, Pharmaceuticals and Other issuers in Asia Astellas Pharma...
Baxalta Incorpo...
Beijing Capital...
Beijing Capital...
Beijing State-o...
Beijing State-o...
China Jianyin I...
China Tourism G...
China Travel Se...
CK Hutchison Ca...
...
28 Jun 2022 Outlook Pharmaceuticals — Global: Revision to stable from positive as patent exposures moderately increase
19 Apr 2022 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Pharmaceutical issuers ADVANZ PHARMA H...
AI Sirona (Luxe...
Almirall, S.A.
AstraZeneca Fin...
AstraZeneca PLC
Cerebro HoldCo ...
Cheplapharm Arz...
Cidron Aida Fin...
Covis Finco S.a...
Covis Parent SC...
...
31 Mar 2022 Rating Action Moody's withdraws credit ratings on multiple entities Absolut Bank (P...
Acron PJSC
Alfa-Bank
Alrosa Finance ...
ALROSA PJSC
AO RAIFFEISENBA...
Atomenergoprom,...
Aton Capital Gr...
Aton Financial ...
Atonline Limite...
...
10 Mar 2022 Rating Action Moody's downgrades the ratings of 95 Russian corporates Acron PJSC
Alrosa Finance ...
ALROSA PJSC
Atomenergoprom,...
Autobann (JSC S...
Avtoban-Finance...
Bashneft PJSOC
Borets Finance ...
Borets Internat...
Celtic Resource...
...
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry